A Jilinde project overview
Topic(s): Research, Service Delivery
Product(s): Oral PrEP
Region(s): Sub-Saharan Africa
Format(s): Factsheet
Countries: Kenya
Source(s): Jhpiego, NASCOP, PSI, ICRH, Avenir Health
Type: Document
This article from BMC Health Services Research describes the impact of a pilot project to permit oral PrEP users to obtain refills at private pharmacies for an additional fee.
From October 2023 to April 2024, MOSAIC supported the Federal Ministry of Health to evaluate the National Oral PrEP Implementation Plan (Jan 2022 – Jan 2024). The purpose of the evaluation was to assess the achievement of priority activities stipulated in the National Oral PrEP Implementation Plan (Jan 2022-Jan 2024) against the intended objectives. The…
This article from Clinical Infectious Diseases reviews 72 prospective studies of daily oral PrEP (TDF/FTC) to evaluate its impact on HIV-1 incidence, drug resistance, adherence, and bone and renal safety in diverse settings.
Short introduction to MOSAIC, a project working across multiple countries to implement user-centered research and research translation efforts to identify, understand, and remove barriers to new product introduction, access, and use; coordinate and provide technical assistance to global, national, and subnational stakeholders to expedite product launch and scale-up; and strengthen the capacity of a wide…
This poster, presented at the INTEREST conference in Cotonou, Benin in 2024, outlines characteristics of seroconversions by women using oral PrEP or the dapivirine vaginal ring in Eswatini.
This article from Global Public Health describes the results of a study to measure the impact of HIV prevention empowerment counselling on PrEP use by adolescent girls and young women in South Africa.
This article from BMC Public Health explores the factors associated with discontinuation of oral PrEP within one month of initiation in two large HIV projects in Nigeria.
This article from BMJ Global Health synthesises lessons learnt from oral PrEP, based on discussions with international stakeholders, to inform the development of a costed rollout plan template for longer acting PrEP methods, including the dapivirine vaginal ring.
The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based daily and event-driven oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and…